Chiang Nai-Jung, Shan Yan-Shen, Hung Wen-Chun, Chen Li-Tzong
Institute of Clinical Medicine, College of Medicine, National Cheng kung University, Tainan, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Institute of Clinical Medicine, College of Medicine, National Cheng kung University, Tainan, Taiwan; Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan.
Int J Biochem Cell Biol. 2015 Oct;67:110-4. doi: 10.1016/j.biocel.2015.06.012. Epub 2015 Jun 19.
Cholangiocarcinoma (CCA) is a malignancy arising from the epithelial cells lining the biliary tract. Despite the existence of variation in incidence and etiology worldwide, its incidence is increasing globally in the past few decades. Surgery is the only curative treatment option for a minority of patients presented with early disease; while moderate effective chemotherapy remains the standard care for patients with locally advanced or metastatic diseases. In this article, we briefly review the molecular alterations that have been described in CCAs focusing on the role of epigenetic modification, including promoter methylation inactivation, histone modification and microRNA, in the carcinogenesis and progression of CCAs. This article is part of a Directed Issue entitled: Epigenetics dynamics in development and disease.
胆管癌（CCA）是一种起源于胆管内衬上皮细胞的恶性肿瘤。尽管全球范围内其发病率和病因存在差异，但在过去几十年中其全球发病率仍在上升。手术是少数早期疾病患者的唯一治愈性治疗选择；而中度有效的化疗仍是局部晚期或转移性疾病患者的标准治疗方法。在本文中，我们简要回顾了胆管癌中已描述的分子改变，重点关注表观遗传修饰在胆管癌发生和发展中的作用，包括启动子甲基化失活、组蛋白修饰和微小RNA。本文是名为《发育和疾病中的表观遗传学动态》的定向专题的一部分。
